Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899574 · ClinicalTrials.gov registry record · Phase 2
Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00899574 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 10 participants.
The verdict
NCT00899574, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine the safety and efficacy of Imiquimod, a Toll-like receptor 7 agonist in breast cancer (for chestwall recurrences or metastases to the skin).
Interventions
- DRUG Imiquimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00899574
The ClinicalTrials.gov registry entry for NCT00899574 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imiquimod is the first listed.
NCT00899574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00899574 about?
NCT00899574 is a clinical study titled "Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases". The purpose of this trial is to determine the safety and efficacy of Imiquimod, a Toll-like receptor 7 agonist in breast cancer (for chestwall recurrences or metastases to the skin).
What is the current status of trial NCT00899574?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2009-05. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00899574?
The interventions under investigation include: Imiquimod (DRUG).
Who is sponsoring clinical trial NCT00899574?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.